SCHEMBL16495288

SCHEMBL16495288

O=C(O)NCCc1cnc(Nc2n[nH]c3c(OCCc4ccccn4)cc(-c4ncccc4Cl)cc23)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.53
JAK1 P23458 1/20 0.53
TYK2 P29597 1/20 0.53
JAK3 P52333 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 2/20 0.37
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK1 P28482 3/20 0.34
KDM4E B2RXH2 2/20 0.34
POLB P06746 2/20 0.33
CHEK1 O14757 1/20 0.33
CDK7 P50613 1/20 0.33
KDR P35968 1/20 0.33
AURKA O14965 1/20 0.32
HPGD P15428 3/20 0.32
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
NTRK1 P04629 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495293 0.91 JAK2 (0.65) JAK2JAK1TYK2JAK3SMN1; SMN2
SCHEMBL9072745 0.90 JAK2 (0.51) JAK2JAK1TYK2JAK3SMN1; SMN2
SCHEMBL16495160 0.89 JAK2 (0.52) JAK2JAK1TYK2JAK3SMN1; SMN2
SCHEMBL2668316 0.89 JAK2 (0.52) JAK2JAK1TYK2JAK3SMN1; SMN2
SCHEMBL16508704 0.88 JAK2 (0.54) JAK2JAK1TYK2JAK3SMN1; SMN2
SCHEMBL16495285 0.88 JAK2 (0.52) JAK2JAK1TYK2JAK3SMN1; SMN2
SCHEMBL2661609 0.87 JAK2 (0.49) JAK2JAK1TYK2JAK3CHEK1
SCHEMBL2661980 0.86 JAK2 (0.49) JAK2JAK1TYK2JAK3MAPK1
SCHEMBL2661442 0.85 JAK2 (0.48) JAK2JAK1TYK2JAK3CHEK1
SCHEMBL2661983 0.85 JAK2 (0.49) JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301155-A1 INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE GCKR, GCK, KHK JAK2 655/4885JAK1 1407/4885TYK2 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.